Literature DB >> 28555433

Structural and activity variability of fractions with different charge density and chain length from pharmaceutical heparins.

Yanlei Yu1,2, Makoto Hirakane2, Daisuke Mori2, Lei Lin2, Fuming Zhang2, Hong Zhang3, Robert J Linhardt4.   

Abstract

Heparin is a structurally complex polysaccharide used as a clinical anticoagulant. It is comprised of a heterogeneous mixture of polysaccharide chains having a variety of sequences and lengths. The production methods and regulatory controls of pharmaceutical heparins have changed over the years. This study assesses the structural and activity uniformity of the polysaccharide chains comprising two contemporary heparin products. The heparin fractions with different sizes and charges were separated with size exclusion and ion exchange chromatography. The fractions were analyzed for their molecular weight properties, di- and tetrasaccharide compositions, and anti-factor IIa and anti-factor-Xa activities. The distribution of these properties through chains of different lengths and ones with different charge density were compared. The results demonstrate that with the increase in heparin purity, activity and molecular weight required by the current pharmacopeia, the uniformity of pharmaceutical heparin products have increased.

Entities:  

Keywords:  Anti-factor IIa activity; Anti-factor-Xa activity; Chromatography; Compositional analysis; Heparin

Mesh:

Substances:

Year:  2017        PMID: 28555433     DOI: 10.1007/s10719-017-9774-7

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  8 in total

1.  2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.

Authors:  Robert J Linhardt
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

2.  Dermatan sulfate of porcine mucosal tissue. n.m.r. observations on its separation from heparin with the aid of heparinase, and its degradation by chondroitinase.

Authors:  K G Ludwig-Baxter; A S Perlin
Journal:  Carbohydr Res       Date:  1991-09-18       Impact factor: 2.104

3.  Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.

Authors:  Yin Chen; Lei Lin; Isaac Agyekum; Xing Zhang; Kalib St Ange; Yanlei Yu; Fuming Zhang; Jian Liu; I Jonathan Amster; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2016-12-20       Impact factor: 3.534

4.  Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species.

Authors:  T Toida; H Yoshida; H Toyoda; I Koshiishi; T Imanari; R E Hileman; J R Fromm; R J Linhardt
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

5.  Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III.

Authors:  R E Edens; J R Fromm; S J Fromm; R J Linhardt; J M Weiler
Journal:  Biochemistry       Date:  1995-02-28       Impact factor: 3.162

6.  Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin.

Authors:  Y S Kim; R J Linhardt
Journal:  Thromb Res       Date:  1989-01-01       Impact factor: 3.944

7.  The US regulatory and pharmacopeia response to the global heparin contamination crisis.

Authors:  Anita Y Szajek; Edward Chess; Kristian Johansen; Gyöngyi Gratzl; Elaine Gray; David Keire; Robert J Linhardt; Jian Liu; Tina Morris; Barbara Mulloy; Moheb Nasr; Zachary Shriver; Pearle Torralba; Christian Viskov; Roger Williams; Janet Woodcock; Wesley Workman; Ali Al-Hakim
Journal:  Nat Biotechnol       Date:  2016-06-09       Impact factor: 54.908

Review 8.  Lessons learned from the contamination of heparin.

Authors:  Haiying Liu; Zhenqing Zhang; Robert J Linhardt
Journal:  Nat Prod Rep       Date:  2009-01-19       Impact factor: 13.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.